Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025DrugsOpen Access

Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJennifer H. CooperriderBDBenjamin A. Derman

Discussion

Loading...

Member takes

Overview

Observational analysis supports MRD negativity as a key endpoint in multiple myeloma, implying improved treatment strategies.

Key Points

  • MRD negativity serves as a significant endpoint in guiding treatment decisions and improving patient outcomes.
  • Phase 3 trials are increasingly focusing on MRD status to optimize multiple myeloma therapy regimens and maintenance strategies.
  • Barriers to implementing MRD testing include cost, complex result interpretation, and insufficient timing guidelines.
  • Prospective randomized studies are crucial for understanding the best incorporation of MRD in multiple myeloma treatment.

Cite This Study

Cooperrider et al. (2025) studied this question.

synapsesocial.com/papers/68c23b8fb210217d64785af0https://doi.org/10.1007/s40265-025-02232-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1What remains matters: Real-world impact of measurable residual disease testing in multiple myeloma2025
  2. 2Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  3. 3Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival2025
  4. 4Delayed and sustained minimal residual disease response predictsfavorable outcomes in newly diagnosed multiple myeloma2025
  5. 5The Role of Minimal Residual Disease (MRD) in Predicting Relapse in Acute Leukemia2025